Strongbridge Biopharma Plc (SBBP) Covered By Cantor Fitzgerald with $14.0 Target; TOURMALINE OIL CORPORATION (TRMLF) SI Increased By 16.36%

December 5, 2017 - By Marguerite Chambers

Among 2 analysts covering Strongbridge B… (SBBP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Strongbridge B… has $18.0 highest and $1200 lowest target. $15’s average target is 134.38% above currents $6.4 stock price. Strongbridge B… had 5 analyst reports since April 25, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, January 25 by H.C. Wainwright. H.C. Wainwright initiated Strongbridge Biopharma plc (NASDAQ:SBBP) on Monday, April 25 with “Buy” rating. The firm earned “Buy” rating on Tuesday, August 8 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, November 15 by H.C. Wainwright. Oppenheimer initiated Strongbridge Biopharma plc (NASDAQ:SBBP) rating on Thursday, August 10. Oppenheimer has “Buy” rating and $1200 target.

TOURMALINE OIL CORPORATION (OTCMKTS:TRMLF) had an increase of 16.36% in short interest. TRMLF’s SI was 2.60 million shares in December as released by FINRA. Its up 16.36% from 2.24 million shares previously. With 4,500 avg volume, 578 days are for TOURMALINE OIL CORPORATION (OTCMKTS:TRMLF)’s short sellers to cover TRMLF’s short positions. It closed at $18.1661 lastly. It is down 0.00% since December 5, 2016 and is . It has underperformed by 16.70% the S&P500.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company has market cap of $254.80 million. The firm offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It currently has negative earnings. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly.

The stock increased 1.59% or $0.1 during the last trading session, reaching $6.4. About 100,048 shares traded. Strongbridge Biopharma plc (SBBP) has declined 15.09% since December 5, 2016 and is downtrending. It has underperformed by 31.79% the S&P500.

Tourmaline Oil Corp., together with its subsidiaries, engages in the acquisition, exploration, development, and production of petroleum and natural gas properties in the Western Canadian Sedimentary Basin. The company has market cap of $5.04 billion. The firm has interests in the properties located in Peace River High, Alberta Deep Basin, and NEBC Montney areas. It has a 20.3 P/E ratio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :